SAN FRANCISCO, April 4, 2013 (GLOBE NEWSWIRE) -- CollabRx, Inc. (Nasdaq:CLRX), a data analytics company focused on informing clinical decision making in molecular medicine, and OncoDNA, SA, a Belgium company that provides DNA next generation sequencing (NGS) tests for clinical use in cancer, today announced a multi-year agreement to purchase CollabRx SaaS-based technology and content resources to be used in conjunction with OncoDNA's cancer mutation panels.
OncoDNA and CollabRx will develop a combined test and medical informatics solution by pairing the results of cancer mutational panels developed by OncoDNA with clinically actionable and dynamically updated knowledge provided by CollabRx. Such knowledge includes the clinical impact of specific mutational profiles and associated therapeutic strategies such as drugs and clinical trials and is supported by CollabRx's large and growing network of over 75 leading clinical practitioners in the U.S. and Europe.
"NGS-based tests are increasingly becoming a routine part of clinical care for cancer patients, but the complexity of the genetic data from tumor mutations is outpacing the ability of physicians to stay current with advanced treatments," said Jean-Pol Detiffe, Founder & CEO of OncoDNA. "We are excited to partner with CollabRx to close this knowledge gap and enable physicians who order OncoDNA tests to access highly credible knowledge provided by CollabRx to aid in the interpretation of test results."The partnership, CollabRx's first outside the United States, will leverage the company's semantic integration platform, a proprietary technology that enables CollabRx scientists and physicians to dynamically update the company's molecular oncology knowledge base with the latest medical and scientific data available in the public domain. "Our agreement with OncoDNA reflects our commitment to partner with best-in-class laboratories and diagnostic companies and is a significant step forward in our strategy to serve high-growth markets outside of the U.S.," said Thomas Mika, Chairman, President & CEO of CollabRx. "We are excited to work with OncoDNA to establish a leadership position in the clinical next generation sequencing market in Europe by providing ordering physicians with clinically relevant interpretation of test results as a seamless part of the reporting process."